Speakers
The Retail Payment Activities Act will task senior leaders at payment service providers (PSPs) with building a lot more compliance into their operations. What’s more, for many this will be the first time their business is subject to such significant oversight.
In this video, Andrew Bernstein and Brigitte Goulard explain why PSPs will soon receive some of the scrutiny that is usually reserved for banks—and what they can do to adapt. Also in the video:
Click here to see other videos and webinars in this series.
Brigitte Goulard (00:06): Why don't you tell us a little bit about what is the Retail Payment Activities Act and what it means?
Andrew Bernstein (00:11): So the Retail Payment Activities Act establishes the legal framework by which the Bank of Canada supervises retail payment providers. The Act was passed in 2021 by Parliament and regulations are expected in 2022. The Bank of Canada, who will take on the role of the regulator, will oversee any retail payment activity that is performed by a payment service provider with a place of business in Canada, or if they deal with Canadian retail payment activities for an end user in Canada, whether that's a natural person or a business. So what is a retail payment activity? It's a payment function that's performed in relation to an electronic funds transfer made in Canadian currency or any other currency, or using a unit that meets certain prescribed criteria. So then what is a payment function? It's activities like maintaining an account in relation to electronic funds transfer, holding funds on behalf of end users, the initiation of an electronic funds transfer, the authorization of other electronic funds transfer, or clearing or settlement services. So that's what the Retail Payment Activities Act deals with. It deals with big entities like PayPal or Amazon and smaller entities that might be doing narrower retail payment activities.
Brigitte Goulard (01:44): So very broad application because it catches a lot of activities and a lot of different bodies. But what's interesting is that the Retail Payment Activities Act has also provided some exemptions for some activities and for some entities. For example, regulated financial institutions, like banks, are not going to be subject because they're already subject to their very own onerous requirements. Closed-loop prepaid cards, like for example your Tim Hortons card that you like to use so often.
Andrew Bernstein (02:13): I have several Tim Hortons cards, maybe I'll take you for a coffee after.
Brigitte Goulard (02:17): Okay, that's good. That sounds good. So those will not be subject to the Retail Payment Activities Act. Cash withdrawals from ATMs, not subject. Agents and mandatories of a payment service provider’s, and finally something very specific, which is the electronic fund transfers for the purpose of giving effect to very specific contracts like derivatives and secured lending agreement. So basically, you can say it's like everything except a few things and those—everything, so all the bodies that will be subject—will be subject probably for the first time ever to an environment that is much more regulated than what they currently deal with. And that's going to be a bit of a shock, I think, to a number of payment service providers, especially those that are more innovative and may not have the experience of dealing with the regulator.
Andrew Bernstein (03:12): So what kind of oversight can those payment service providers expect from the Bank of Canada?
Brigitte Goulard (03:16): So I think there's like five things that they need to think about. The first one is registration. Every single payment service provider that does the activity that you've mentioned, and that is not one of the bodies that is exempted, will need to register with the Bank of Canada and the bank will keep a public registry of all of those entities so that people can go and check to make sure that they are one of the bodies that is supervised. The next ones two that I'm going to talk about, are probably the core of what’s in the Retail Payment Activities Act. The first one is the mitigation of operational risk and dealing with incidents. So a PSP will need to file with the Bank of Canada policies, procedures that will mitigate operational risk and deal with incidents such as, for example, they lose access to the funds that are being transferred, they lose some data, that type of risk will need to be addressed in such a policy, and they will need to impose some controls. So there's a very good framework to make sure that the risk is contained. The third aspect, which is also very important, is the protection of end-user funds. So let's say, for example, you take milk for coffee, but you refuse to pay for my coffee, and I pay you for my coffee through PayPal.
Andrew Bernstein (04:37): Okay.
Brigitte Goulard (04:37): So the end-user fund that would be transferred to you would need to be separated distinct from PSPs own funds. So there’s going to be segregation of those funds. They're going to be subject to specific rules. So basically, people will have a certain safety net to make sure that their funds are protected. Finally, the fourth one is that there will be lots of reporting. So if financial institutions who are used to dealing with regulated bodies, regulators, know that the regulators love their reports. So be prepared, PSPs that are out there, you will be asked to do a lot of reports—annual reports, reports when you change your activities—so that there's going to be a layer of reporting that you're going to be required to do. And finally, fees. The Bank of Canada will be turning to the PSPs to fund their supervisory activities. So you can expect some fees. In your expertise as an administrative law lawyer, you have dealt with a lot of regulatory bodies before.
Andrew Bernstein (05:44): Yes.
Brigitte Goulard (05:44): So what do you think of the enforcement tools that are currently provided in the Retail Payment Activities Act? Sufficient, not sufficient?
Andrew Bernstein (05:53): Yeah, I would describe them as typical. And I think we would find that most of the time these are sufficient. They range from fairly benign, like requesting information or a special audit, or verifying certain aspects of compliance, to a little more heavy-handed, like asking a PSP to enter into a compliance agreement for the purpose of implementing compliance measures. And why would a PSP do that? A PSP would do that because the hammer that the Bank of Canada holds is administrative monetary penalties. And the RPAA actually provides for pretty significant administrative monetary penalties, up to $10 million for certain PSPs that commit violations of the Act. So, you know, what's interesting is those fines are very significant and much higher than you see even in most criminal law fine-type offenses. But because the purpose of the penalties is to enforce compliance and not to punish, you don't have the protections that a criminal defendant might have. Now, one important thing is that due diligence is a defense in relation to a violation. So it's not enough to show, just strictly speaking, non-compliance. The PSP will have the option of saying, “Actually we tried very hard and this just didn't work out.” And the other tool that not every regulator has is the actual obligation to make violations public. So other regulators may have the option where if you commit a violation, they don't have to name you or they don't even have to say that a violation occurred. The Bank of Canada will have an obligation to explain that a PSP committed a violation. So I consider those very robust tools.
Andrew Bernstein (07:59): You're a former regulator, so I guess you loved your reports. What are your views on those tools and what advice would you have for payment service providers to prepare themselves?
Brigitte Goulard (08:11): So you're right, those tools when I was a Deputy Commissioner of the Financial Consumer Agency of Canada were very similar. You know, compliance agreements, penalties and so on. I think the three steps that I would really recommend to the PSPs is to minimize the risk of non-compliance. The first is, understand your requirements. Understand what is expected of you. The legislation, for example, with respect to operational risk, is very specific on the type of controls that you need to have, the type of information that you need to include in your policies. Understand what that is. And then through that understanding, make sure that when you draft those policies that they actually reflect the risk that you have. It's not just “Oh no, the regulators are asking us this, you know, let's do this kind of on this side of the table for a half an hour and then we're done.” You know, the time you take is very important because that will definitely go a long way to demonstrating due diligence. The second one is once you've got that document, implement those policies and procedures. Ensure that you've got those controls, ensure that they're reviewed, sufficient, when needed. Make sure that your people understand what is requested of them. Do the training that is required, do the communications. That's really critical where I've seen often where there's been an issue is that the policy procedure looks great, however, the implementation where what's on paper doesn't necessarily match what the technology is doing, so make sure that's there. And finally, have those controls in place. The legislation does provide or impose certain controls, but continue testing it, especially for PSPs where their product is really all about technology.
Andrew Bernstein (10:01): Right.
Brigitte Goulard (10:01): It's not about having a register and you take the money and make sure you count it properly. It's all about technology and there were so many times when I was a regulator where, you know, the intention of complying was there. The information was completely laid out properly. The disclosures were happening, the policies and procedures. But somebody had tinkered in the background with the technology, which ended up impacting something that they weren't expecting. So make sure you do the controls and the test so that you do comply. So before we close it up, Andrew, last words of wisdom to make sure that they don't end up in—well, it'd be nice if they ended up in your office, but hopefully not end up in our office because of a potential violation.
Andrew Bernstein (10:43): Exactly. Come for a social visit. Don't come because you've received a notice of violation.
Brigitte Goulard (10:49): Words of wisdom.
Andrew Bernstein (10:50): This is a new regime. It's a robust regime. And there's going to be bumps in the road as the regulator and the regulated test the boundaries of the new regime. You probably don't want to be one of the test cases. So I would strongly urge people to do what Brigitte suggested, make sure that things are in order, not just in order in theory, but in order in practice. And that enables you to focus on your business rather than focusing on regulatory problems that might arise.
Le mois dernier, le Canada a publié sa première Stratégie industrielle de défense (la Stratégie), qui souligne l’engagement du Canada à développer une base industrielle de défense solide et à stimuler la croissance économique. Ces efforts pourraient aussi comprendre le renforcement de l’état de préparation à la biodéfense et aux contre-mesures médicales, ce qui pourrait constituer des débouchés pour le secteur canadien des sciences de la vie en raison de l’importance accordée aux capacités nationales en ce sens et de la nécessité d’atténuer les risques d’urgences sanitaires.
Comme indiqué dans les bulletins précédents, le quatrième pilier de la Stratégie est axé sur la « sécurisation des chaînes d’approvisionnement pour les intrants et les biens clés » par le renforcement de la production nationale et le stockage de ressources. L’accent est mis tout particulièrement sur les contre-mesures médicales, en précisant que nos « alliés ont établi un lien explicite entre l’état de préparation à la biodéfense et aux contre-mesures médicales et leur sécurité économique et nationale, en élaborant de nouvelles stratégies et de nouveaux mécanismes pour faire progresser ces travaux ». Les contre-mesures médicales désignent divers produits réglementés pouvant être utilisés pour protéger la population lors d’une situation d’urgence de grande ampleur, comme l’éclosion d’une maladie ou une attaque impliquant des armes chimiques, biologiques ou nucléaires. Il peut s’agir de vaccins, de médicaments thérapeutiques et produits biologiques, de dispositifs de tests diagnostiques, des équipements de protection individuelle ou industrielle, et d’autres dispositifs médicaux. Les contre-mesures médicales sont essentielles à la réduction et à l’atténuation des dommages lors d’une urgence de santé publique.
Pendant et après la pandémie de COVID-19, le Canada a mis en place plusieurs nouvelles voies réglementaires comme mécanismes d’accélération des approbations de produits médicaux, ce qui pourrait offrir au gouvernement des options pour déployer des contre-mesures médicales afin de faire face aux risques pour la santé publique. Au début de la pandémie, Santé Canada a émis diverses ordonnances provisoires pour permettre l’importation et la vente de médicaments et de dispositifs médicaux qui n’avaient pas eu l’approbation des voies réglementaires traditionnelles. Or, Santé Canada a plutôt fait confiance aux voies d’approbation réglementaire et de l’exemption de certaines exigences en homologation de produits des pays impliqués dans la transaction. Beaucoup de ces règles provisoires ont depuis été officiellement intégrées à la réglementation en vertu de la Loi sur les aliments et drogues et ont été appliquées bien après la COVID-19. Conformément au Règlement sur les aliments et drogues, Santé Canada tient à jour la Liste des maladies qui menacent la santé publique et utilisera une procédure d’autorisation modifiée pour les médicaments d’urgence de santé publique pouvant traiter les affections figurant sur la liste. De même, le Règlement sur les instruments médicaux a établi une liste d’instruments médicaux répondant à un besoin urgent de santé publique, ce qui permet à Santé Canada d’autoriser la commercialisation de ces instruments de manière accélérée. Ces outils réglementaires sont utilisés automatiquement quand une situation médicale présente un grand risque pour la santé publique au Canada et nécessite une action immédiate pour contrer ce risque.
La stratégie prévoit que le Canada adoptera une approche proactive en matière de planification en amont des crises sanitaires. Le gouvernement entend s’assurer que les produits médicaux sont déjà disponibles au Canada afin qu’ils puissent être distribués rapidement en cas d’urgence. D’autres modifications récentes au Règlement sur les aliments et drogues permettent de prépositionner au Canada tous les médicaments d’urgence en santé publique, ce qui signifie qu’ils peuvent être importés dans des installations d’entreposage canadiennes avant que leur mise sur le marché n’ait été autorisée. La Stratégie s’appuie sur ces fondements, en faisant référence à l’organisme existant Préparation aux crises sanitaires Canada (PCSC), un organisme opérationnel spécial au sein d’Innovation, Sciences et Développement économique Canada (ISDE), et à un nouveau Fonds des sciences de la vie, lesquels « collaborent avec des partenaires internationaux et de soutenir l’élaboration et la production de contre-mesures médicales ». PCSC supervise la Stratégie en matière de biofabrication et de sciences de la vie du Canada, qui vise à développer un secteur national des sciences de la vie fort et compétitif doté de capacités de biofabrication de pointe, en mettant l’accent sur la capacité à se préparer et à faire face aux futures priorités et crises sanitaires. Dans cette optique, il y aura des occasions pour les fabricants de nouer des collaborations de recherche et des accords commerciaux ou d’approvisionnement liés aux contre-mesures médicales financées par des programmes fédéraux.
Étroitement lié aux capacités nationales, le pilier III de la stratégie implique « Investissement ciblé pour renforcer un secteur canadien de la défense novateur », avec la promesse que le gouvernement fédéral « soutiendr[a] la recherche et le développement, protéger[a] la propriété intellectuelle, soutiendr[a] les petites et moyennes entreprises, investir[a] dans les compétences et la formation, et encourager[a] les exportations afin de créer un secteur de la défense agile et concurrentiel à l’échelle mondiale ». La nécessité de favoriser le développement de la propriété intellectuelle (PI) et la conservation des droits du Canada est mentionnée à plusieurs reprises dans la Stratégie. Par exemple, la Stratégie prévoit l’établissement de partenariats officiels avec l’industrie canadienne qui « [assureront] la propriété et le contrôle nationaux de la propriété intellectuelle (PI) et des capacités essentielles. » La Stratégie reconnaît l’immense talent des établissements canadiens et la précieuse recherche qui y est menée actuellement et qui est déjà financée par des subventions de recherche d’organismes tels que le Conseil de recherches en sciences naturelles et en génie et les Instituts de recherche en santé du Canada, et fait aussi référence à l’engagement de 1,6 milliard de dollars pour de nouveaux fonds de recherche dans le budget de 2025. Cette prise de conscience de la nécessité de promouvoir et de soutenir l’innovation au Canada laisse présager des possibilités de financement, notamment dans les domaines où le Canada accuse un retard en matière de production nationale et où des engagements d’investissement et de fabrication au Canada peuvent être pris.
Dans les prochains mois, nous prévoyons que le gouvernement du Canada publiera d’autres directives et des mesures de suivi. L’équipe de défense des conservateurs poursuivra sa couverture de perspectives sur la défense au Canada en publiant une analyse supplémentaire pour donner des précisions sur l’incidence de la Stratégie sur de multiples secteurs.